+ Larger Font | - Smaller Font
Share


Sorry, Your Requested Page Was Not Found.
Greetings! We apologize for the inconvenience, but the page, Press Release Aileron Therapeutics Announces Proof Of Concept Clinical Data From Ongoing Alrn 6924 Phase 1b Trial Presented In Late Breaking Presentation At The Eortc Nci Aacr Annual Symposium is no longer available. Please use our search box below to find related content and browse the list of related news stories. Depending on the topic, news articles are deleted 3 - 18 months after the created date. We prefer to keep content fresh and current and not keep old news. Thanks for visiting today.
Search RobinsPost News & Noticias


Press Release Aileron Therapeutics Announces Proof Of Concept Clinical Data From Ongoing Alrn 6924 Phase 1b Trial Presented In Late Breaking Presentation At The Eortc Nci Aacr Annual Symposium | RobinsPost News & Noticias

Aileron Therapeutics Announces CEO Transition


Currently, LTI-03 is being evaluated in a Phase 1b clinical trial for the treatment of ... EU and Fast Track Designation in the US. This press release may contain forward-looking statements of Aileron ... Read More

Astria Therapeutics Announces Positive Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b/2 Trial of STAR-0215 for HAE


March 25, 2024--(BUSINESS WIRE)--Astria Therapeutics ... today announced positive initial proof-of-concept results from the ALPHA-STAR Phase 1b/2 clinical trial evaluating STAR-0215, a monoclonal ... Read More

Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a SPOTLIGHT Clinical Study of Briquilimab in Chronic Inducible Urticaria


March 19, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics ... that the first patient has been dosed in Jasper’s Phase 1b/2a (SPOTLIGHT) clinical study of subcutaneous briquilimab for the treatment ... Read More

Aileron Therapeutics Inc ALRN


We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ... Read More

RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual Meeting


RAPT Therapeutics is a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant ... Read More

Nuvectis Pharma Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant ARID1a-Mutated Ovarian Cancer


today announced preliminary data from the ongoing Phase 1b clinical trial of NXP800 in patients with platinum resistant ARID1a-mutated ovarian cancer, a deadly disease of unmet medical need. Read More

Sonnet BioTherapeutics Announces Early Safety Data…


Safety in the Phase 1b part of Sonnet's double-blind, randomized, controlled trial of SON‑080 was reviewed by the study's Data Safety Monitoring Board ... over the course of the trial. This press ... Read More

Aileron Therapeutics Announces CEO Transition


Currently, LTI-03 is being evaluated in a Phase 1b clinical trial for the ... Looking Statements This press release may contain forward-looking statements of Aileron Therapeutics, Inc. (“Aileron ... Read More

Astria Therapeutics Announces Positive Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b/2 Trial of STAR-0215 for HAE


CloseCurlyDoubleQuote; ALPHA-STAR is a dose-ranging proof-of-concept trial in adults with HAE Type ... the potential significance of the initial results from the Phase 1b/2 ALPHA-STAR clinical trial ... Read More

Aileron Therapeutics Announces CEO Transition


March 12, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (“Aileron”) (NASDAQ: ALRN), a biopharmaceutical ... LTI-03 is being evaluated in a Phase 1b clinical trial for the treatment ... Read More


Blow Us A Whistle


Comments (Whistles) Designed By Disqus